



The Nifty previous session ended 0.86% down at 11,153.65. It opened on a negative note and continued trading with negative bias towards finishing off with another bearish body candle. Chart pattern suggests, it may continue trading within a price band of 11,250-11,050. However, further decline below 11,050 is likely.

On the Nifty hourly chart; it is still trading below the critical MA band. However, the RSI already has reached oversold zone, which means it may see intraday pullback towards critical resistances where it is likely to find sellers. Further, considering the direction of the ADX we prefer being cautious on rise around.

Nifty patterns on multiple time frames suggest; it finished off on a weaker note. Chart pattern suggests, it might get into range-bound oscillation in the price band of 11,050-11,250.

Nifty Crucial Supports & Resistances-

Supports- 11050, 10970 Resistances- 11250, 11350

Open positional calls-

T+7 Positional Buy-
|Cash Segment| BHARTI AIRTEL @
482-480, TGT- 510, SL- 465


T+3 Positional Buy-
|Cash Segment| HDFC BANK @
1042-1040, TGT- 1080, SL- 1020

T+5 Positional Sell-
|Futures Segment| HCL TECH Fut @
805-810, TGT- 750, SL- above 840

T+5 Positional Sell-
|Futures Segment| EXIDE Fut @ 161
-162, TGT- 152, SL- above 167

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

Indian equity markets ended off the lowest point of the day but ended with declines for the fourth straight session, in-line with the global sentiment.

The NSE Nifty 50 index fell 0.9% to 11,153. The broader markets represented by the NIFTY 500 Index ended 1.06% lower, ending at 9214. NIFTY IT was the top gainer, gaining by 0.69%, followed by NIFTY Pharma gaining by 0.66%. NIFTY Media was the top loser, losing by 2.60%.

TCS was the top gainer, gaining by 2.34%, followed by HCL Technologies and Grasim which gained by 2.29% & 1.71% respectively. Zee Enterprise was the top loser, losing by 6.45%, followed by Gail India and Adani ports, which fell by 4.59% & 4.47% respectively.

The Advance: Decline ratio stood at 426:1392

Market Turnover (In Crore) 22-09-2020

Name	Last	Previous
NSE Cash	*NA	64169.39
NSE F&O	2188928.38	1807273.05
BSE Cash	3,126.08	3,369.79
BSE F&O	*NA	144.80

FII Derivatives Flow (In Crore) 21-09-2020*

Instrument	Purchase	Sale	Net
Index Future	6720.07	6288.41	431.66
Index Option	205002.09	205790.29	788.2
Stock Future	33173.51	33503.88	330.37
Stock Option	9922.26	9679.49	242.77

Institutional Flow (In Crore) 21-09-2020*

Institution	Purchase	Sale	Net
FII	5230.5	5770.31	539.81
DII	4333.23	4851.18	517.95

*Data not updated till 5:35

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
TCS	2.34	1.27	7499927	4800617
HCL Technologies	2.29	3.57	21882919	15045750
Grasim Industries	1.71	1.21	3313571	3107092
Tech Mahindra	1.68	1.18	9053627	7056247
Cipla	1.24	4.74	14483986	15306230


NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Tata Motors	3.16	10.31	87298376	57414490
Bharti Infratel	4.42	10.91	11769233	6915692
Adani Ports	4.47	5.77	4670215	2904602
Gail India	4.59	8.63	23856234	12472780
Zee Enterprise	6.45	9.36	54161525	24967880

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	37734.08	300.06	0.79	3.36	1.82	8.09	0.74
Nifty	11153.65	96.90	0.86	3.20	1.92	8.17	1.07
BSE M Cap	14284.41	247.18	1.70	4.86	4.48	9.35	1.16
BSE S Cap	14509.26	238.08	1.61	5.56	0.79	16.60	9.88
Nifty MC 100	16507.75	257.45	1.54	5.09	2.79	11.56	1.07
BSE Auto	17390.14	311.90	1.76	4.24	2.90	14.12	1.81
BSE Capgoods	13232.51	335.32	2.47	5.83	6.62	3.80	26.77
BSE FMCG	10846.52	93.42	0.85	4.69	7.60	0.45	3.93
BSE Metal	8140.30	96.18	1.17	6.70	11.44	9.67	12.63
BSE Oil&Gas	12490.60	305.93	2.39	6.13	6.46	3.95	10.09
BSE Healthcare	19614.95	0.79	0.00	1.54	2.01	18.34	50.69
BSE Power	1645.08	26.92	1.61	4.53	5.63	3.61	14.40
BSE Realty	1659.44	30.39	1.80	5.15	6.23	0.03	18.68
BSE ConsDur	23015.77	265.94	1.14	4.84	0.73	12.39	10.07
BSE Bank	24054.51	242.22	1.00	5.82	4.84	2.66	26.27
BSE IT	20031.25	180.68	0.91	1.96	9.68	38.25	28.58

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.67	0.00	0.50	1.44	6.51	5.56	61.13
UK	0.19	0.03	19.75	13.36	8.74	2.59	70.06
Brazil	3.63	0.14	3.90	5.01	1.20	27.43	5.45
Japan	0.02	0.00	0.00	28.57	55.88	25.00	107.25
Australia	0.83	0.02	2.81	4.16	5.69	4.38	18.73
India	6.01	0.00	0.07	0.35	1.25	2.28	11.45
Switzerland	0.49	0.01	1.99	4.90	3.15	22.08	35.69
Germany	0.51	0.02	3.40	6.89	0.99	16.63	1.73

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.59	0.19	0.25	0.08	1.00	3.31	3.60
USD Index	93.50	0.16	0.17	0.48	0.27	3.65	5.09
YUAN	6.77	0.03	0.46	0.12	2.14	4.34	5.07
GBP	1.29	0.00	0.26	0.30	1.63	3.06	3.39
EUR	1.18	0.00	0.13	0.77	0.27	4.40	6.94
YEN	104.46	0.19	0.18	0.94	1.46	2.35	2.96

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1314.00	18.00	1.39	2.50	11.28	15.66	38.34
Baltic Dirty	439.00	2.00	0.45	3.09	9.11	11.49	46.98
SG Dubai HY	0.35	0.11	23.91	275.00	252.17	252.17	103.93

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	27147.70	509.72	1.84	3.02	2.80	4.31	0.79
Nasdaq	10778.80	14.48	0.13	2.51	4.71	7.18	32.78
S&P 500	3281.06	38.41	1.16	3.03	3.42	5.23	9.66
FTSE100	5819.15	14.59	0.25	4.70	3.05	6.82	20.78
CAC40	4812.69	21.38	0.45	5.02	1.69	2.73	15.42
DAX	12666.06	124.93	1.00	4.16	0.76	3.30	1.60
Mexico IPC	35517.77	499.58	1.39	2.25	6.77	6.84	18.46
Brazil Bovespa	96990.80	1298.99	1.32	3.27	4.46	1.74	7.47
Russian RTS	1205.82	24.59	2.08	3.82	4.45	4.05	12.45
Japan Nikkei	23360.30	40.93	0.18	0.20	1.92	3.92	5.80
Hang Seng	23716.85	233.84	0.98	4.11	5.56	3.24	10.28
Taiwan Index	12645.51	149.61	1.17	1.56	0.30	9.27	15.70
Shanghai Comp	3274.30	42.63	1.29	0.65	3.15	10.42	8.91
KOSPI	2332.59	56.80	2.38	4.54	1.21	9.68	11.53
Malaysia KLCI	1505.78	6.35	0.42	0.37	4.52	0.36	5.74
Jakarta Comp	4934.09	65.27	1.31	3.27	6.42	0.31	20.82
Philippine SE	5894.28	15.04	0.25	2.06	1.85	7.14	25.12
Thai Exch	1267.63	7.53	0.59	1.44	2.43	6.25	22.53

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	39.94	0.63	1.60	4.34	5.67	1.29	31.24
BRENT Crude	41.89	0.45	1.09	3.36	6.77	3.01	28.54
Natural Gas	1.88	0.04	2.13	20.66	27.17	0.74	22.82

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1906.22	6.61	0.35	2.47	1.78	8.63	25.64
Silver(\$/Ounce)	24.28	0.44	1.79	10.55	9.39	37.05	34.92
Aluminium	1739.25	13.85	0.79	1.28	0.77	10.57	1.97
Copper	6718.50	134.25	1.96	1.41	3.18	15.25	16.44
Zinc	2440.75	80.50	3.19	0.67	0.41	17.15	5.57
Lead	1863.50	24.40	1.29	1.88	4.42	5.40	11.65

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	113.90	1.90	1.70	6.49	4.92	13.67	2.43
Cotton	65.55	0.31	0.48	1.34	1.98	9.52	3.20
Sugar	13.29	0.16	1.22	4.56	0.75	4.98	0.91
Wheat	560.50	5.75	1.04	4.13	4.77	12.55	7.79
Soybean	1028.00	5.50	0.54	3.68	13.62	16.92	9.33

Tata Motors rolls out 300,000th unit of Tiago from Sanand plant

Tata Motors rolled out the 3,00,000th unit of its mid-sized hatchback Tiago from the Sanand passenger vehicles manufacturing plant in Gujarat. The car maker had started production of Tiago from this facility in February 2016. Tata Motors on Monday rolled out the 3,00,000th Tiago from its Sanand facility in Gujarat. Launched in 2016. It was the first product under the Impact design philosophy and brought to the market a host of segment first features at the time of its launch in 2016.

PSBs get more retail credit inquiries than private banks during Jul-Aug

The state-run lenders are seeing faster pick up in retail credit inquiries than their private counterparts on quicker reopening of branch network, a report by a credit information company (CIC) said on Tuesday. Despite the inroads done by digital alternatives, through which lenders are receiving inquiries and even disbursing loans online, branch offices continue to play an important role. The lenders get in touch with CICs while doing diligence on every credit proposal. Public (sector) lenders saw the biggest rebound in inquiries in July and August 2020, most likely because they were early in recommencing operations than their private and NBFC (non-bank finance companies) counterparts. Inquiries from over a dozen state-run lenders for the two months were at 102 per cent of the same observed in January-February this year and 118 per cent of that in the same period a year ago.

NTPC to set up manufacturing industrial parks in its power plants

NTPC Ltd seeks to set up manufacturing industrial parks within its power plants at Solapur in Maharashtra, Kudi in Karnataka and Gadwara in Madhya Pradesh. The company has invited expression of interest (EOI) from MSMEs and other Indian companies for setting up the energy intensive manufacturing plants such as bulk chemicals like ammonia, urea, gypsum, geopolymer, cooling and heating solutions, aluminium and mineral processing like ceramics, tiles, pottery, brick and glass etc in the industrial parks to be developed on a pilot basis. Besides offering reliable electricity supply at competitive prices, the parks will provide readily available infrastructural services like water supply, road and rail network, internet connectivity along with various testing facilities. NTPC will enter into a separate agreement with prospective entities for allotment of spaces. These industrial parks will be subjected to requisite approvals from respective state governments and the central government. NTPC will process these approvals based on responses received in the EOI.

Strides Pharma Science arm gets USFDA nod for tension headache tablets

Strides Pharma Science on its subsidiary, Strides Pharma Global Pte Ltd, has received approval from the US health regulator for Butalbital, Acetaminophen, and Caffeine tablets, used to treat tension headache. The approved product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Butalbital, Acetaminophen, and Caffeine tablets of Actavis Laboratories FL Inc. Strides Pharma Global Pte Ltd, Singapore, has received approval for Butalbital, Acetaminophen, and Caffeine tablets USP in the strengths of 50 mg/325 mg/40 mg from the United States Food and Drug Administration (USFDA)

Bayer's Aflibercept injection gets DCGI nod for Diabetic Macular Edema indication

Bayer in India has received approval from the Drugs Controller General of India (DCGI) for its intravitreal injection Aflibercept, for the treatment of a new indication Diabetic Macular Edema (DME). DME occurs when high blood sugar levels damage capillaries that leak fluid into the retina, resulting in swelling and blurred vision. The approval of Aflibercept injection for intravitreal use presents a new and alternative treatment option to currently available therapies, for patients with DME. Intravitreal Aflibercept offers patients impacted by diabetic vision loss a new option to be proactive and stay ahead of the disease. The company's pharmaceuticals division in India operates as Bayer Zydus Pharma, a joint venture between Bayer and Zydus Cadila.

Jio unleashes post-paid tariff war, targets high paying Airtel, Vi users

Reliance Jio Infocomm (Jio) has rolled out post paid tariff plans to woo the high revenue customers who till now were on Bharti Airtel and Vodafone Idea (VIL)'s postpaid plan. The Mukesh Ambani-led telco has come up with a gamut of offerings which includes family packs and access to OTT platforms, a first from Jio which so far had mostly focussed on prepaid customers. There can't be a more opportune time to introduce JioPostpaid Plus. After having earned the trust of close to 400 million satisfied customers in the prepaid smartphone category, we want to extend our customer obsession to the postpaid category. The post paid turf is set to be the next battle ground since these customers bring in the high average revenue per user (ARPU) - a key metric - and therefore will be Jio's target. Interestingly, the new postpaid tariffs come in a time when VIL has been talking of hikes in prices as well. Jio which has about 400 customers has an ARPU of Rs 140 compared to Vodafone Idea's Rs 114 and Airtel's Rs 157. It is also aiming to reach a base of 500 million subscribers and for that, postpaid tariffs will get the telco an expanded target base.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Texmaco Rail & Engineering Ltd	Cash dividend of INR0.10 effective 23-09-2020
KSE Ltd	Cash dividend of INR20 effective 23-09-2020
Amrutanjan Health Care Ltd	Corporate meeting effective 23-09-2020
Bharat Forge Ltd	Corporate meeting effective 23-09-2020
Coal India Ltd	Corporate meeting effective 23-09-2020
DEN Networks Ltd	Corporate meeting effective 23-09-2020
Dhunseri Tea & Industries Ltd	Corporate meeting effective 23-09-2020
DLF Ltd	Corporate meeting effective 23-09-2020
Inox Leisure Ltd	Corporate meeting effective 23-09-2020
Jagran Prakashan Ltd	Corporate meeting effective 23-09-2020
KDDL Ltd	Corporate meeting effective 23-09-2020
Khadim India Ltd	Corporate meeting effective 23-09-2020
Usha Martin Ltd	Corporate meeting effective 23-09-2020
Zensar Technologies Ltd	Corporate meeting effective 23-09-2020

Domestic Events

- No Events

Global Events

- Japan Jibun Bank Flash PMI for September 2020.
- The U.S. MBA Mortgage Application for September 18, 2020.
- The U.S. Markit Flash PMI for September 2020.
- Euro Area Markit Flash PMI for September 2020.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com